Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

A new study found users who take the drug-made by Pfizer- for a year or more are 3.5 times more likely to develop a meningioma, the most common type of brain tumour.

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

More than 30 years ago, when Jean-Pascal Tricoire first came to China, his friends gave him the Chinese ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

The second healthcare sector IPCEI – approving up to €403 million of State aid by five Member States, including France, ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...